Evidence map›Paper›PMID 40384272›Full record

ArticleAdvanced healthcare materials2025

CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer.

Yue Qing, Ke Jiang, Hua Jiang, Yaru Zhao, Chu-Hu Lai, Alexandra Aicher, Zonghai Li, Christopher Heeschen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue QingCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Ke JiangCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Hua JiangState Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yaru ZhaoCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Chu-Hu LaiPrecision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 404328, Taiwan.
Alexandra AicherPrecision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 404328, Taiwan.
Zonghai LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Christopher HeeschenCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.ORCID 0000-0002-1158-8554

Funding

Fondazione AIRC per la ricerca sul cancro ETS IG 2023 ID 28933H2020 European Research Council Pa-CSC 233460Hsinchu Science Park Bureau, Ministry of Science and Technology, Taiwan NSTC 113-2314-B-039-073-MY3National Natural Science Foundation of China-Xinjiang Joint Fund 82130074Natural Science Foundation of Jilin Province 82250710179
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with no current effective treatment options. Chimeric antigen receptor (CAR) T cell therapy represents a powerful immunotherapeutic approach but faces major limitations in PDAC due to complex manufacturing and reduces efficacy within the highly immunosuppressive tumor microenvironment (TME). Small extracellular vesicles (sEVs) derived from CAR-T cells present a novel strategy to address these challenges. Here, CLDN18.2 CAR-T cells are used to generate CAR-sEVs via ultracentrifugation. The purified CAR-sEVs exhibit typical sEV size and morphology, containing established sEV markers, and carry functional CAR proteins along with cytotoxic molecules such as granzyme B. In vitro, CAR-sEVs displays potent cytotoxic activity against murine CLDN18.2

Indexed as

Carcinoma, Pancreatic DuctalClaudinsExtracellular VesiclesImmunotherapyImmunotherapy, AdoptivePancreatic NeoplasmsReceptors, Chimeric AntigenAnimalsCell Line, TumorFemaleHumansMiceTumor MicroenvironmentClaudinsReceptors, Chimeric AntigenCAR‐T cellsexosomesextracellular vesiclespancreatic ductal adenocarcinoma

Identifiers

PMID40384272
PMCPMC12184078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.